Leading Alzheimer's Disease Scientist Joins NeuroCog Trials

Published: Jul 09, 2018

DURHAM, N.C., July 9, 2018 /PRNewswire/ -- Specializing in Alzheimer's Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials (NCT) providing thought leadership in Neurodegenerative Disorders. With more than 25 years of research dedicated to this therapeutic area, Dr. Welsh-Bohmer lends the highest level of scientific expertise to the continued development of effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring later in life.

Her current work includes neuropsychology leadership in the Takeda Pharmaceutical's TOMMORROW STUDY, the largest, industry-sponsored, Phase 3 clinical trial of its kind with a focus on the secondary prevention of mild cognitive impairment (MCI) due to AD. The methods her team developed for this study have filled an information void and have implications for accelerating global clinical trials in Alzheimer's Disease prevention.

"Dr. Welsh-Bohmer has been an esteemed colleague and partner on several global clinical trials and I am delighted to have her join NCT as we offer pharmaceutical companies development solutions addressing this enormous unmet need," said Co-Founder and CEO, Dr. Richard Keefe. "Seen as one of the most challenging areas of drug development, the Alzheimer's treatment and prevention landscape requires quickly evolving regulatory guidance and disruptive therapeutic approaches. As one of the true leaders in the AD scientific research field, Dr. Welsh-Bohmer brings that expertise to our team."

Dr. Welsh-Bohmer's work as Director of the Joseph and Kathleen Bryan Alzheimer's Disease Research Center (Bryan ADRC) at Duke University Medical Center was centered around discovering the biological basis of Alzheimer's disease and developing methods to enhance early diagnosis and speed drug discovery. She also serves as the Director of Alzheimer's Disease Clinical Trials within the Duke Clinical Research Institute.

Dr. Welsh-Bohmer received her PhD in psychology from the University of Virginia and completed postdoctoral training in clinical neuropsychology at the University of Iowa. She is board certified in the practice of clinical neuropsychology through the American Board of Professional Psychology.

About NeuroCog Trials
NeuroCog Trials (NCT) is a global cognition and clinical assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications. NCT has provided its products and services, including regulatory consulting, site screening, rater training and certification, translation, eCOA and data services in more than 100 clinical trials in over 25 countries. Founded in 2005, NCT is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.


                 Contact Mary Ziegler

                  Office                                 +1 919 433 2429

     Switchboard                                         +1 919 401 4642

                   Email Mary.Ziegler@neurocogtrials.com

                 Website www.neurocogtrials.com


View original content with multimedia:http://www.prnewswire.com/news-releases/leading-alzheimers-disease-scientist-joins-neurocog-trials-300677930.html

SOURCE NeuroCog Trials


Back to news